Riociguat HCl (formerly BAY 63-2521, BAY 632521; Adempas), the hydrochloride salt of Riociguat, is an oral bioavailable and first-in-class soluble guanylate cyclase (GC) stimulator approved for use in the treatment of ipulmonary hypertension. Riociguat is currently in clinical development by Bayer. The Phase III clinical trials investigated the use of riociguat as a new approach to treat two forms of pulmonary hypertension (PH): chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH). Riociguat constitutes the first drug of a novel class of sGC stimulators.

纯度：≥98%